NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Prostarm Info Systems Q3 Standalone PAT Jumps 105% YoY to ₹15.96 Crore
Prostarm Info Systems reported a robust performance for Q3 FY26, with standalone revenue from operations surging 110.8% year-on-year to ₹159.34 crore. Standalone net profit followed suit, doubling to ₹15.96 crore compared to ₹7.79 crore in the same period last year. On a consolidated basis, the nine-month revenue reached ₹281.31 crore, showing steady growth over the previous year's ₹268.63 crore. The company maintains its focus on customized power electronic solutions, which remains its sole reportable business segment.
முக்கிய அம்சங்கள்
Standalone Revenue from operations grew 110.8% YoY to ₹159.34 crore in Q3 FY26.Standalone Net Profit increased by 104.9% YoY to ₹15.96 crore from ₹7.79 crore.Quarter-on-quarter (QoQ) standalone revenue saw a massive jump from ₹64.61 crore in Q2 FY26.Standalone Earnings Per Share (EPS) for the quarter rose to ₹2.88 from ₹1.82 YoY.Consolidated 9-month revenue stood at ₹281.31 crore, up from ₹268.63 crore in the previous year period.
👀 கவனிக்க வேண்டியவை
The significant jump in quarterly revenue and profitability suggests strong execution and demand in the power electronics segment. Investors should monitor the sustainability of these margins and the order book to determine if this represents a permanent shift in the company's growth trajectory.
Prostarm Info Systems Declared L-1 Bidder for INR 4.29 Crore WBMSC Project
Prostarm Info Systems Limited has been declared the L-1 bidder for a contract from West Bengal Medical Services Corporation (WBMSC). The project involves the supply, installation, and commissioning of 10 KVA UPS systems and batteries at 137 Block Primary Health Units across West Bengal. The total contract value is INR 4.29 Crores, with an execution timeline of 180 days. This order includes a 3-year warranty on the equipment, strengthening the company's service portfolio in the public healthcare sector.
முக்கிய அம்சங்கள்
Total contract value is approximately INR 4.29 CroresProject covers 137 Block Primary Health Units across the state of West BengalExecution period is set for 180 days from the date of awardScope includes supply, installation, testing, and commissioning of 10 KVA UPS systemsContract includes a comprehensive 3-year warranty on both UPS and batteries
👀 கவனிக்க வேண்டியவை
Investors should track the timely execution of this 180-day project as it provides short-term revenue visibility. Continued success in securing government healthcare infrastructure contracts could be a positive growth driver for the company.
Star Health Appoints Himanshu Walia and Amitabh Jain as Whole-time Directors for 5 Years
Star Health has received IRDAI approval to appoint Mr. Himanshu Walia and Mr. Amitabh Jain as Whole-time Directors and Key Managerial Personnel for a five-year term starting February 11, 2026. Mr. Walia, the current Chief Marketing Officer, has been with the company since 2007 and brings over 22 years of insurance experience. Mr. Jain, the current Chief Operating Officer and a former founding member of ICICI Lombard, has over 25 years of experience in financial services. These appointments strengthen the leadership team by elevating experienced internal executives to the board level.
முக்கிய அம்சங்கள்
Appointment of two Whole-time Directors for a fixed term of 5 years effective February 11, 2026Mr. Himanshu Walia (CMO) brings 22+ years of experience and has been with Star Health since 2007Mr. Amitabh Jain (COO) has 25+ years of experience and was a founding member of ICICI LombardAppointments have received formal regulatory approval from IRDAI
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move for leadership continuity and operational stability. Monitor the company's execution on digital transformation and market share growth under this strengthened leadership team.
Star Cement Q3 FY26 PAT Jumps to ₹74 Cr; EBITDA Per Ton Rises to ₹1,600
Star Cement reported a robust performance for Q3 FY26, with revenue growing 22.4% YoY to ₹880 crores. The company's EBITDA per ton saw a significant jump to ₹1,600 compared to ₹1,000 in the previous year, driven by improved realizations in the Northeast market. Net profit surged to ₹74 crores from ₹9 crores YoY, despite a 28% drop in subsidy income. Management confirmed the commissioning of the Silchar plant in February 2026, which is expected to bolster future volumes and subsidy benefits.
முக்கிய அம்சங்கள்
Revenue increased to ₹880 crores from ₹719 crores YoY, while PAT surged to ₹74 crores from ₹9 crores.EBITDA per ton improved significantly to ₹1,600 from ₹1,000 in the same quarter last year.Total cement sales volume grew to 12.31 lakh tons, with Northeast sales accounting for 9.36 lakh tons.Silchar plant commissioning is scheduled for February 2026, with subsidy benefits expected to kick in after 7-8 months.Incentive income dropped 28% YoY to ₹33 crores following the GST rate reduction from 28% to 18%.
👀 கவனிக்க வேண்டியவை
Investors should consider the strong operational efficiency and upcoming capacity expansion at Silchar as positive long-term catalysts. The company remains a dominant player in the Northeast, though monitoring logistics costs and the impact of new regional capacity is advised.
IndoStar Q3FY26: Disbursements Up 20% QoQ to ₹1,117 Cr; PPOP Grows 44% YoY
IndoStar Capital Finance reported strong operational growth in Q3FY26, with disbursements rising 20% QoQ to ₹1,117 crore and AUM reaching ₹7,692 crore. While Pre-provision operating profit (PPOP) surged 43.5% YoY to ₹85.2 crore, Profit After Tax (PAT) fell 27.7% YoY to ₹8.3 crore, primarily due to a one-time ₹4.8 crore regulatory wage code impact. The company demonstrated improved efficiency with a 67 bps YoY reduction in cost of funds to 10.09% and a 70 bps improvement in yields. Asset quality remains stable with Gross Stage 3 at 4.06% and a very healthy Capital Adequacy Ratio of 41.4%.
முக்கிய அம்சங்கள்
Disbursements grew 20% QoQ to ₹1,117 crore, led by 21% growth in Vehicle Finance.Pre-provision operating profit (PPOP) increased 43.5% YoY to ₹85.2 crore driven by yield expansion.Cost of funds improved by 67 bps YoY to 10.09% through the 'LEAP' cost optimization initiative.Standalone PAT of ₹8.3 crore includes a one-time ₹4.8 crore impact from regulatory changes in the Wage Code.Capital Adequacy Ratio (CAR) stands strong at 41.4% with low leverage of 1.2x following warrant conversions.
👀 கவனிக்க வேண்டியவை
Investors should look past the one-time PAT dip and focus on the robust 44% YoY growth in operating profit and improving NIMs. The company's strong capital position and declining cost of funds suggest a positive trajectory for future profitability.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
IndoStar Q3FY26: NIM Expands to 8.6% Despite PAT Dip to ₹8.3 Crore
IndoStar Capital Finance reported a PAT of ₹8.3 crore for Q3FY26, a decline from ₹11.4 crore in the previous year. While overall AUM saw a slight year-on-year dip to ₹7,692 crore, Net Interest Margins (NIM) showed significant improvement, rising to 8.6% from 5.4% a year ago. The company is successfully transitioning to a retail-centric model, with Micro LAP AUM growing over 6x to ₹128 crore. Asset quality remains a point of focus as Gross Stage 3 assets rose sequentially to 4.06% from 3.04% in Q2FY26.
முக்கிய அம்சங்கள்
Net Interest Margin (NIM) improved significantly to 8.6% in Q3FY26 compared to 5.4% in Q3FY25.Micro LAP segment showed robust growth with AUM reaching ₹128 crore, up from ₹19 crore in the previous year.Capital Adequacy Ratio remains very healthy at 41.4%, providing a strong cushion for future growth.Gross Stage 3 assets improved year-on-year to 4.06% but showed a sequential increase from 3.04% in Q2FY26.Total disbursements for the quarter stood at ₹1,117 crore, showing a recovery from the previous quarter's ₹927 crore.
👀 கவனிக்க வேண்டியவை
Investors should monitor the sequential rise in Stage 3 assets and the impact of the retail transition on bottom-line profitability. While the strong capital position and improving NIMs are positive, consistent PAT growth is yet to materialize.
IndoStar Capital Finance Approves Q3 FY26 Results; Deploys ₹201 Cr for Growth
IndoStar Capital Finance has approved its unaudited financial results for the quarter and nine months ended December 31, 2025. The company disclosed the full utilization of approximately ₹201.33 crore raised through two preferential issues in late 2025. These funds were entirely directed toward growth objectives, specifically for onward lending in commercial vehicle, housing, and SME finance. The absence of any deviation in fund usage reflects management's commitment to expanding the core lending business.
முக்கிய அம்சங்கள்
Approved Q3 and 9M FY26 unaudited standalone and consolidated financial results.Utilized ₹149.99 crore raised on Nov 24, 2025, for onward lending and capital augmentation.Utilized ₹51.33 crore raised on Dec 20, 2025, for growth objectives in retail and SME segments.Reported zero deviation in the utilization of proceeds from preferential issues.Trading window for designated persons to reopen on February 12, 2026.
👀 கவனிக்க வேண்டியவை
Investors should review the specific profit and NPA figures in the full results to assess the quality of the expanded loan book. The rapid deployment of capital indicates strong demand in their target lending segments.
IndoStar Capital Reports Nil Deviation in Utilization of Rs 201.3 Cr Raised via Warrants
IndoStar Capital Finance has confirmed zero deviation in the utilization of funds raised through preferential issues of warrants during the quarter ended December 31, 2025. The company raised approximately Rs 150 crore on November 24 and an additional Rs 51.3 crore on December 20, totaling over Rs 201 crore. All proceeds were deployed toward growth objectives, specifically for onward lending and augmenting the capital base. This transparency, monitored by CRISIL Ratings, reinforces management's commitment to its stated business expansion strategy.
முக்கிய அம்சங்கள்
Confirmed NIL deviation in the utilization of Rs 201.33 crore raised via preferential issue of warrants.Raised Rs 149.99 crore on Nov 24, 2025, and Rs 51.33 crore on Dec 20, 2025.100% of the raised funds were utilized for 'Growth Objectives' including onward lending, exceeding the minimum 75% threshold.CRISIL Ratings Limited acted as the monitoring agency, verifying the fund deployment.Funds are being used to support commercial vehicle financing, housing finance, and SME lending portfolios.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the disciplined and transparent deployment of capital into the company's core lending business. Monitor the next few quarterly earnings to see how this capital infusion translates into AUM growth and interest income.
Megastar Foods Q3FY26 PAT Surges 580% YoY to ₹3.06 Cr; Revenue Up 52%
Megastar Foods reported a stellar performance for Q3FY26, with revenue growing 52.3% YoY to ₹141.21 crore. Net profit (PAT) witnessed a massive jump of 580% YoY, reaching ₹3.06 crore compared to ₹0.45 crore in the same quarter last year. For the nine-month period (9MFY26), the company has already surpassed its full-year FY25 performance, recording a revenue of ₹386.51 crore and a PAT of ₹7.06 crore. The company continues to leverage its state-of-the-art Buhler machinery plant and strong relationships with MNC clients like Nestle and ITC.
முக்கிய அம்சங்கள்
Q3FY26 Revenue increased by 52.3% YoY to ₹14,121 lakhs from ₹9,270 lakhs.Q3FY26 PAT grew nearly 7x to ₹306 lakhs from ₹45 lakhs in the previous year's quarter.9MFY26 EBITDA stands at ₹2,604 lakhs, already exceeding the full FY25 EBITDA of ₹2,229 lakhs.The company operates a high-capacity 710 MT/day processing facility with 85% utilization for refined flour.Maintains a diversified product mix with Maida contributing 70% and Organic products gaining traction at 14%.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to maintain these high margins as it scales, given the significant operational leverage shown this quarter. The strong growth trajectory and premium client base make it a compelling growth story in the packaged food processing sector.
Prostarm Declared L-1 Bidder for ₹13.43 Cr Solar Project from South Eastern Railway
Prostarm Info Systems Limited has been declared the L-1 bidder for a solar power project by South Eastern Railway. The contract, valued at INR 13.43 Crores, covers the supply, installation, and erection of a solar power plant at SRC Jurisdiction (Phase 2). The project timeline is 12 months and includes a five-year Comprehensive Maintenance Contract (CMC). This domestic order represents a significant win for the company in the renewable energy infrastructure space.
முக்கிய அம்சங்கள்
Declared L-1 bidder for a South Eastern Railway project valued at INR 13.43 CroresProject involves supply, installation, and erection of a solar power plant at SRC JurisdictionExecution timeline is 12 months with an additional 5-year maintenance contractThe order was secured through a domestic competitive bidding process
👀 கவனிக்க வேண்டியவை
Investors should monitor the official contract signing and subsequent execution milestones over the next 12 months. This win provides healthy revenue visibility and demonstrates the company's competitiveness in government tenders.
Star Cement Declares Re. 1 Interim Dividend and Approves Promoter Reclassification
Star Cement has declared a second interim dividend of 100% (Re. 1 per equity share) for FY 2025-26, with the record date set for February 12, 2026. The company also approved the reclassification of 29 members of the Chamaria Group, holding a 6.052% stake, from the Promoter to the Public category. Financially, the company recognized an exceptional item of ₹552.03 lakhs due to the implementation of new Labour Codes. The dividend is expected to be paid to eligible shareholders by March 8, 2026.
முக்கிய அம்சங்கள்
Declared 2nd interim dividend of Re. 1 per share (100% of face value) for FY 2025-26Fixed February 12, 2026, as the Record Date for dividend eligibilityApproved reclassification of 29 Chamaria Group members (6.052% stake) to Public CategoryRecognized an exceptional expense of ₹552.03 lakhs related to new Labour Code regulationsDividend payment to be completed within 30 days of declaration, by March 8, 2026
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date to qualify for the Re. 1 per share payout. The promoter reclassification is a structural change that may improve the stock's public float and liquidity over time.
Starteck Finance Q3 Net Profit Surges 106% YoY to ₹7.48 Crore
Starteck Finance reported a robust performance for the quarter ended December 31, 2025, with consolidated net profit doubling to ₹7.48 crore from ₹3.63 crore in the previous year. Total income grew by 65% YoY to ₹15.66 crore, significantly bolstered by a sharp rise in other income. The company's core revenue from operations also saw healthy growth of 16.2% YoY. For the nine-month period, the company has already surpassed its previous full-year profit, reaching ₹18.38 crore.
முக்கிய அம்சங்கள்
Consolidated Net Profit increased 105.9% YoY to ₹747.71 lakh from ₹363.11 lakh.Total Income rose 65.1% YoY to ₹1,566.19 lakh, driven by a surge in Other Income to ₹548.09 lakh.Revenue from operations grew 16.2% YoY to ₹1,018.10 lakh compared to ₹876.13 lakh in Q3 FY25.Basic EPS for the quarter improved to ₹7.54 from ₹3.66 in the corresponding quarter of the previous year.Nine-month consolidated net profit reached ₹1,838.10 lakh, representing a 103.9% growth over the same period last year.
👀 கவனிக்க வேண்டியவை
The company shows strong earnings momentum and efficient cost management, making it a positive watch for growth-oriented investors. However, investors should monitor the sustainability of 'Other Income' which significantly contributed to the bottom line this quarter.
Megastar Foods Approves Q3 and Nine Months FY26 Unaudited Financial Results
Megastar Foods Limited has approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting was held on February 5, 2026, and the results were reviewed by the Audit Committee and statutory auditors M/s Nitin Mahajan & Associates. While the specific financial figures were not detailed in the cover letter, the company has confirmed the completion of the limited review process. Investors should now access the full financial statements on the exchange to evaluate the company's growth trajectory.
முக்கிய அம்சங்கள்
Board approved unaudited standalone and consolidated financial results for Q3 and 9M FY26.Statutory auditors M/s Nitin Mahajan & Associates issued Limited Review Reports for the period.The board meeting was conducted between 11:00 AM and 1:00 PM on February 5, 2026.Results have been submitted to both BSE and NSE as per SEBI Listing Regulations.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed financial tables in the full report to analyze revenue growth and margin performance. Compare the Q3 results against the previous year's corresponding quarter to assess the company's operational momentum.
Strides Pharma Receives USFDA EIR for New York Facility with VAI Classification
Strides Pharma's US subsidiary has received an Establishment Inspection Report (EIR) from the USFDA for its Chestnut Ridge facility in New York, marking the successful closure of the audit. The inspection, conducted in December 2025, resulted in a Voluntary Action Indicated (VAI) status following the company's response to Form 483. Significantly, the audit included a pre-approval inspection for Drug-Device Combination capabilities, specifically covering recent filings in the Nasal Sprays domain. This clearance supports the company's US growth strategy for specialized products like hormones and controlled substances.
முக்கிய அம்சங்கள்
USFDA inspection conducted from December 17 to December 23, 2025, at the Chestnut Ridge, NY facility.Inspection outcome classified as VAI (Voluntary Action Indicated), signifying formal closure of the audit.Included pre-approval inspection for Drug-Device Combinations, facilitating entry into the Nasal Sprays market.The facility supports high-margin products including Liquids, Gels, Hormones, and Controlled Substances.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory milestone that de-risks the US pipeline for complex generics. Monitor for upcoming product approvals and launches in the Nasal Spray and Hormone categories from this facility.
Blue Star Q3FY26 Revenue Up 4.2% to ₹2,925 Cr; PAT Impacted by ₹56 Cr Exceptional Item
Blue Star reported a modest 4.2% YoY revenue growth to ₹2,925.31 crore for Q3FY26, despite a subdued market environment. Net profit declined to ₹80.55 crore from ₹132.46 crore, primarily due to a one-time exceptional charge of ₹56.35 crore related to labor code changes for gratuity and leave encashment. While the Projects segment saw revenue growth, its margins compressed to 6.8% due to project mix, though the Unitary Products segment saw margin improvement to 8.5%. Management expressed optimism for a strong Q4, driven by the upcoming summer season and inventory buildup following energy label changes.
முக்கிய அம்சங்கள்
Consolidated revenue grew 4.2% YoY to ₹2,925.31 crore, while EBITDA stood at ₹220.72 crore with a 7.5% margin.Net profit fell to ₹80.55 crore after accounting for a ₹56.35 crore non-recurring exceptional item related to new Labour Codes.Unitary Products (ACs) segment margins improved to 8.5% from 8.1% YoY despite flat revenue, aided by cost-control measures.Carried-forward order book remains stable at ₹6,898.74 crore, representing a modest 1.3% growth over the previous year.Management anticipates price hikes in Q4FY26 due to INR depreciation and rising commodity costs, despite GST reductions for consumers.
👀 கவனிக்க வேண்டியவை
Investors should focus on the non-operational nature of the PAT decline and monitor the company's ability to pass on cost increases in Q4. The stable order book and margin improvement in the AC segment suggest resilience despite a subdued quarter.
Star Health Q3 FY26 PAT Jumps to ₹449 Cr; Combined Ratio Improves to 98.9%
Star Health reported a robust Q3 FY2026 with Gross Written Premium (GWP) increasing 23% YoY to ₹5,047 crore, supported by a 45% surge in fresh business. Profit After Tax (PAT) under IND AS rose significantly to ₹449 crore from ₹87 crore in the previous year, driven by a 320 bps improvement in the combined ratio to 98.9%. The company maintained its market leadership with a 31.3% retail health market share and improved its 9M PAT by 87% YoY to ₹966 crore. Management highlighted a strategic shift towards high-margin retail business, which now constitutes 95% of the total portfolio.
முக்கிய அம்சங்கள்
Q3 GWP grew 23% YoY to ₹5,047 crore, with fresh business growth at 45% and renewal growth at 17%.Combined ratio improved by 320 bps YoY to 98.9% in Q3 FY26, leading to an underwriting profit of ₹46 crore.9M FY26 PAT increased 87% YoY to ₹966 crore, supported by an investment yield of 9.6%.Retail loss ratio decreased to 68.4% in Q3 FY26, down 103 bps from the previous year.Digital D2C channel grew 35% YoY in 9M FY26, contributing 20% of all fresh business premiums.
👀 கவனிக்க வேண்டியவை
Investors should note the significant operational turnaround as the company achieved underwriting profitability and a sub-100% combined ratio. The strong growth in the high-margin retail and digital segments, coupled with disciplined claims management, makes the stock a strong play on the expanding Indian health insurance sector.
Strides Pharma Q3 FY26: Record EBITDA of ₹236 Cr; PAT Jumps 38% YoY as Margins Hit 60%
Strides Pharma Science Limited reported a strong Q3 FY26 performance, achieving its highest-ever quarterly EBITDA of ₹236 crores, a 12% YoY increase. While total revenue growth was modest at 3.6% due to a planned scale-down of the institutional business, operational PAT surged by 38% YoY. The company's focus on profitability led to gross margins reaching 59.8% and an EPS of ₹41.4. Notably, the Ex-US markets grew 20% YoY to $64 million, significantly narrowing the gap with the US market which remained flat at $70 million.
முக்கிய அம்சங்கள்
Highest ever quarterly EBITDA of ₹236 crores with margins expanding 160 bps YoY to 19.8%.Operational PAT grew by 38% YoY, supported by gross margins touching the 60% mark.Ex-US revenue increased 20% YoY to $64 million, now contributing 47% of total Q3 revenues.Net debt reduced by ₹170 crores during the quarter, bringing the Debt/EBITDA ratio down to 1.59x.Appointed Peter Hardwick as CEO of North American Business to lead the next growth phase beyond $400 million.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant structural improvement in profitability and the successful debt reduction trajectory. The company's reduced dependence on the US market and focus on high-margin regulated markets make it a strong candidate for long-term growth.
Five-Star Business Finance Q3 FY26: PAT at ₹277 Cr; Collection Efficiency Improves to 99.01%
Five-Star Business Finance reported a PAT of ₹277 crores for Q3 FY26, a marginal 1% YoY increase, while deliberately slowing disbursements to ₹976 crores to focus on asset quality. Collection efficiency on the current book improved to 99.01%, and the current portfolio proportion rose slightly to 81.77%, signaling stabilization in softer buckets. The company successfully reduced its cost of funds by 50 bps YoY to 9.12% and secured a $100 million sanction from the Asian Development Bank. Management expects to resume growth acceleration within the next 1-2 quarters as collection frameworks fully mature.
முக்கிய அம்சங்கள்
PAT for Q3 FY26 stood at ₹277 crores with a healthy ROA of 7% and ROE of 15.8%.Disbursements decreased 18% QoQ to ₹976 crores as the company prioritized collection vertical strengthening.Unique customer collection efficiency (excluding NPAs) improved from 96.5% to 97.26% QoQ.Cost of incremental debt reached a low of 8.19%, while total net worth crossed the ₹7,000 crore milestone.Collection workforce expanded significantly to 2,452 officers compared to 1,329 in the previous year.
👀 கவனிக்க வேண்டியவை
Investors should look for a reversal in the disbursement slowdown in H1 FY27 as a signal of management's confidence in asset quality. The significant reduction in cost of funds and strong liquidity provide a solid cushion against current micro-finance sector headwinds.
Blue Star Reports Unauthorized Access to Product Installation Data
Blue Star Limited has reported a cybersecurity incident involving unauthorized access to its product installation data, detected on January 31, 2026, at 10:30 p.m. The company immediately took steps to restrict access and is currently working with cybersecurity experts to assess the potential impact. A thorough root cause analysis is underway to understand the breach's origin. The disclosure was made as a matter of good governance under SEBI Listing Regulations, and the company is monitoring the situation closely.
முக்கிய அம்சங்கள்
Unauthorized access to product installation data detected on January 31, 2026, at 10:30 p.m.Immediate measures implemented to restrict access and secure the data environmentEngagement with cybersecurity experts for impact assessment and root cause analysisDisclosure made under Regulation 30 of SEBI Listing Regulations as a transparency measure
👀 கவனிக்க வேண்டியவை
Investors should monitor subsequent updates to determine if the breach involves sensitive customer information or results in operational disruptions. While the immediate impact appears contained, the final assessment from cybersecurity experts will be crucial for long-term risk evaluation.
Blue Star Limited Notifies Shareholders of Q3 and Nine-Month FY26 Financial Results
Blue Star Limited has formally communicated its financial results for the third quarter and nine months ended December 31, 2025, to its shareholders. The Board of Directors approved the unaudited standalone and consolidated financial results during their meeting on January 29, 2026. The company has provided direct access to the detailed financial reports, a press release, and an investor presentation via its website. This communication serves as a procedural update to ensure transparency and provide shareholders with comprehensive performance data.
முக்கிய அம்சங்கள்
Board of Directors approved Q3FY26 financial results on January 29, 2026Communication dispatched to all registered shareholders on January 30, 2026Results cover both standalone and consolidated performance for the period ending December 31, 2025Public access provided to the investor presentation and detailed press release via company website
👀 கவனிக்க வேண்டியவை
Investors should review the detailed investor presentation and press release on the company's website to analyze specific revenue and margin trends. Focus on the performance of the cooling products segment ahead of the peak summer season.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
